Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q3 2019 Earnings Presentation
8 slides from Agilent Technologies's earnings presentation, 2019
Slide 1: Agilent Technologies Q3'19 Results Presentation
Agilent Technologies Q3'19 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth o
Slide 3: Agilent Results Q3'19
Agilent Results Q3'19 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q3'19 Financial Metrics Q3'19 Headlines • Revenues: $1.27B, +6.2% y/y • Growth: Pharma and Applied Markets, led by core(1)(2),+5.8% reported (+1.5% M&A, -1.9% Environmental & Forensics, tracke
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Core revenue performance reflected broad strength Instrumentation and Informatics in Pharma, Environmental & Forensics markets, offset for Analytical Laboratories by ongoing expected weakness in China Food and a difficult compare in Chemical & Energy. •
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) • Continued strong revenue performance across Analytical Laboratory Consumables and Services both services and consumables. Broad growth across all markets and regions led by China. • Operating Margin in the quarter was 26.2%(1)(2), up 310 bps versus last year. • ACG gr
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Strong core revenue growth driven by strength in Pathology, Genomics, and Nucleic Acid Manufacturing the Clinical & Diagnostic market, solid growth in Pathology and Genomics, and very strong demand in Pharma for oligo-manufacturing (NASD). • Operating Margin fo
Slide 7: Growth in a $52B Market – Q3'19 Results by End Market
Growth in a $52B Market – Q3'19 Results by End Market Strong Gains in broader Pharma, Diagnostics and Environmental Markets Analytical Laboratory End Markets Q3'19 revenues: +6% y/y on core(2) basis Pharma & Biotech: Up 13% with strength in small and large molecule Pharma, Services, Chemistries
Slide 8: Q4'19 and FY19 Guidance and Forward-looking Considerations
Q4’19 and FY19 Guidance and Forward-looking Considerations Based on July 31, 2019 Exchange Rates Q4’19 Guidance (1) FY Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,310 $1,330 Net Revenue ($M) $5,105 $5,125 Y/Y Core Revenue Growth (2) 1.5% 3.0% Y/Y Core Revenue Growth (2) 4.4% 4